Alimera Sciences/ALIM

$3.72

0.26%
-
1D1W1MYTD1YMAX

About Alimera Sciences

Alimera Sciences, Inc. is a commercial-stage global pharmaceutical company. The Company is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. ILUVIEN is an intravitreal implant that treats patients by delivering a continuous micro dose of the corticosteroid fluocinolone acetonide (FAc) in the eye, for up to 36 months. ILUVIEN is inserted into the back of the patient's eye in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. DME is also treated by Laser photocoagulation, a retinal procedure in which a laser is used to apply a burn, or a pattern of burns, to cauterize leaky blood vessels to reduce edema.

Ticker

ALIM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Richard Eiswirth

Employees

150

Headquarters

Alpharetta, United States

Alimera Sciences Metrics

BasicAdvanced
$194.47M
Market cap
-
P/E ratio
-$2.63
EPS
1.17
Beta
-
Dividend rate

What the Analysts think about Alimera Sciences

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
88.17% upside
High $8.00
Low $5.00
$3.72
Current price
$7.00
Average price target

Alimera Sciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-5.57% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$23.3M
33.14%
Net income
$-1.3M
-87%
Profit margin
-5.57%
-90.25%

Alimera Sciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 6.98%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.54
-$0.71
-$1.32
-$0.06
-
Expected
-$0.34
-$0.32
$0.02
-$0.06
$0.00
Surprise
61.19%
121.88%
-8,900%
-6.98%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Alimera Sciences stock

Buy or sell Alimera Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing